A recent subanalysis of the DAPA-HF study, a trial primarily investigating the effects of the sodium–glucose cotransporter 2 (SGLT2)-inhibitor dapagliflozin on heart failure in individuals with and without type 2 diabetes, found that dapagliflozin significantly reduced UA by 50.0 μmol/l (0.84 mg/dl) over 12 months (p<0.001) compared with placebo. This evidence concerns the gene SLC5A2 and heart failure.